Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Capmatinib in Hepatic Impairment
NCT02474537Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of capmatinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Novartis. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration, Area under the plasma concentration-time curve from time zero to infinity and 5 more. Started Jun 2015; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02474537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474537.